[144/A] Hims & Hers Health, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144/A from Hims & Hers Health, Inc. (HIMS) reports a proposed sale of 154,958 common shares through Goldman Sachs & Co. LLC on 09/22/2025, with an aggregate market value of $9,161,116.96. The filing shows 217,641,958 shares outstanding. The securities to be sold were acquired mainly as compensation: multiple Restricted Stock Unit grants on 09/15/2025, 09/15/2024, 06/15/2024 and cashless exercises of stock options on 02/24/2022 and 03/01/2023. The filing also discloses sales by Oluyemi Okupe during the past three months totaling several transactions, including a 145,000-share sale on 09/15/2025 for $8,026,083.50. The notice includes the seller's representation that no undisclosed material adverse information is known.

Insights

Securities Analyst

TL;DR: Insider proposes to sell 154,958 shares valued at $9.16M; recent large insider sales were disclosed but filing shows standard compensation-origin shares.

The filing is a routine Rule 144 notice documenting proposed sale logistics and the provenance of the shares, primarily from restricted stock unit grants and prior option exercises. Material items are the size of the proposed sale and the disclosed outstanding share count, which allow calculation of ownership impact if aggregated with other holdings. Recent transactions by Oluyemi Okupe, including a 145,000-share sale that generated $8.03M, are explicitly reported and relevant for measuring recent insider liquidity.

Corporate Governance Expert

TL;DR: Disclosure is compliant and transparent, showing compensation-origin shares and multiple recent sales by an insider.

The document provides clear lineage for the securities (RSUs and option exercises) and identifies the broker and execution date for the proposed sale. The seller's attestation about material nonpublic information is included as required. This filing does not by itself indicate governance issues but it does document substantial insider selling activity that stakeholders may note.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144/A

144/A: Filer Information

Filer CIK
Filer CCC
Previous Accession Number Of The Filing
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144/A: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144/A: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	154958	9161116.96	217641958	09/22/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144/A: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/15/2025	Acquired as compensation -- Restricted Stock Units	Issuer			11747	09/15/2025	Compensation
Common	09/15/2025	Acquired as compensation -- Restricted Stock Units	Issuer			4110	09/15/2025	Compensation
Common	09/15/2025	Acquired as compensation -- Restricted Stock Units	Issuer			5153	09/15/2025	Compensation
Common	09/15/2025	Acquired as compensation -- Restricted Stock Units	Issuer			2574	09/15/2025	Compensation
Common	02/24/2022	Acquired as compensation -- Stock Options	Issuer			80976	02/24/2022	Compensation -- Cashless exercise / same-day sale
Common	03/01/2023	Acquired as compensation -- Stock Options	Issuer			15230	03/01/2023	Compensation -- Cashless exercise / same-day sale
Common	09/15/2024	Acquired as compensation -- Restricted Stock Units	Issuer			19028	09/15/2024	Compensation
Common	06/15/2024	Acquired as compensation -- Restricted Stock Units	Issuer			16140	06/15/2024	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144/A: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	06/23/2025	23107	1091767
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	07/07/2025	11581	540498.84
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	07/14/2025	11581	552417.98
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	08/13/2025	11581	556419.19
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	08/26/2025	11581	505968.38
Oluyemi Okupe 2269 Chestnut Street Suite 523 San Francisco CA 94123	Common	09/15/2025	145000	8026083.5

144/A: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)